Skip to main content
SpringerLink
Log in

Preclinical and clinical studies on cytokine-induced killer cells for the treatment of renal cell carcinoma

  • Review
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

Renal cell carcinoma (RCC) is the most common malignancy of adult human kidney, which accounts for more than 2 % of all cancers. RCC generally does not respond well to conventional chemotherapy and radiotherapy. Cytokine-induced killer (CIK) cells are ex vivo activated lymphocytes with potent activity against various tumors and minimal side effects. Here, we summarize the data on preclinical and clinical efficacy of CIK cells for RCC treatment. Our preclinical data show that CIK cells have potent anti-tumor activity in vitro and in an in vivo nude mouse xenograft model. Clinical studies for the treatment of RCC patients indicate that CIK cell therapy can induce favorable responses with no serious side effects. These studies suggest that CIK cells may become a valuable strategy for the treatment of patients with RCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Alvarnas, J.C., Y.C. Linn, E.G. Hope, and R.S. Negrin. 2001. Expansion of cytotoxic CD3 + CD56 + cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation 7: 216–222.

    Article  CAS  PubMed  Google Scholar 

  • Bukowski, R.M., W. Sharfman, S. Murthy, P. Rayman, R. Tubbs, J. Alexander, G.T. Budd, J.S. Sergi, L. Bauer, V. Gibson, et al. 1991. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. Cancer Research 51: 4199–4205.

    CAS  PubMed  Google Scholar 

  • Conti, A., M. Santoni, C. Amantini, L. Burattini, R. Berardi, G. Santoni, S. Cascinu, and G. Muzzonigro. 2013. Progress of molecular targeted therapies for advanced renal cell carcinoma. Biomed Research International 2013: 419176.

    Article  PubMed Central  PubMed  Google Scholar 

  • Dillman, R., P. Schiltz, C. Depriest, N. Barth, L. Beutel, C. De Leon, A. O’connor, and S. Nayak. 2004. Tumor-infiltrating lymphocytes and interleukin-2: Dose and schedules of administration in the treatment of metastatic cancer. Cancer Biotherapy and Radiopharmaceuticals 19: 730–737.

    Article  CAS  PubMed  Google Scholar 

  • Eisen, T., C.N. Sternberg, C. Robert, P. Mulders, L. Pyle, S. Zbinden, H. Izzedine, and B. Escudier. 2012. Targeted therapies for renal cell carcinoma: Review of adverse event management strategies. Journal of the National Cancer Institute 104: 93–113.

    Article  CAS  PubMed  Google Scholar 

  • Escudier, B., T. Eisen, C. Porta, J.J. Patard, V. Khoo, F. Algaba, P. Mulders, V. Kataja, and E.G.W. Group. 2012. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 23(Suppl 7): vii65–vii71.

    Article  PubMed  Google Scholar 

  • Escudier, B., T. Eisen, W.M. Stadler, C. Szczylik, S. Oudard, M. Staehler, S. Negrier, C. Chevreau, A.A. Desai, F. Rolland, T. Demkow, T.E. Hutson, M. Gore, S. Anderson, G. Hofilena, M. Shan, C. Pena, C. Lathia, and R.M. Bukowski. 2009. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. Journal of Clinical Oncology 27: 3312–3318.

    Article  CAS  PubMed  Google Scholar 

  • Escudier, B., A. Pluzanska, P. Koralewski, A. Ravaud, S. Bracarda, C. Szczylik, C. Chevreau, M. Filipek, B. Melichar, E. Bajetta, V. Gorbunova, J.O. Bay, I. Bodrogi, A. Jagiello-Gruszfeld, N. Moore, and A.T. Investigators. 2007. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. The Lancet 370: 2103–2111.

    Article  Google Scholar 

  • Figlin, R.A., I. Kaufmann, and J. Brechbiel. 2013. Targeting PI3 K and mTORC2 in metastatic renal cell carcinoma: New strategies for overcoming resistance to VEGFR and mTORC1 inhibitors. International Journal of Cancer 133: 788–796.

    Article  CAS  Google Scholar 

  • Figlin, R.A., J.A. Thompson, R.M. Bukowski, N.J. Vogelzang, A.C. Novick, P. Lange, G.D. Steinberg, and A.S. Belldegrun. 1999. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. Journal of Clinical Oncology 17: 2521–2529.

    CAS  PubMed  Google Scholar 

  • Franceschetti, M., A. Pievani, G. Borleri, L. Vago, K. Fleischhauer, J. Golay, and M. Introna. 2009. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Experimental Hematology 37: 616–628. e612.

    Article  CAS  PubMed  Google Scholar 

  • Goedegebuure, P.S., L.M. Douville, H. Li, G.C. Richmond, D.D. Schoof, M. Scavone, and T.J. Eberlein. 1995. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: A pilot study. Journal of Clinical Oncology 13: 1939–1949.

    CAS  PubMed  Google Scholar 

  • Hartmann, J.T., and C. Bokemeyer. 1999. Chemotherapy for renal cell carcinoma. Anticancer Research 19: 1541–1543.

    CAS  PubMed  Google Scholar 

  • Hoffman, D.M., B.J. Gitlitz, A. Belldegrun, and R.A. Figlin. 2000. Adoptive cellular therapy. Seminars in Oncology 27: 221–233.

    CAS  PubMed  Google Scholar 

  • Hudes, G.R. 2009. Targeting mTOR in renal cell carcinoma. Cancer 115: 2313–2320.

    Article  CAS  PubMed  Google Scholar 

  • Jemal, A., F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman. 2011. Global cancer statistics. CA: A Cancer Journal for Clinicians 61: 69–90.

    Google Scholar 

  • Kane, C.J., K. Mallin, J. Ritchey, M.R. Cooperberg, and P.R. Carroll. 2008. Renal cell cancer stage migration: Analysis of the National Cancer Data Base. Cancer 113: 78–83.

    Article  PubMed  Google Scholar 

  • Kim, H.M., J.S. Kang, J. Lim, S.K. Park, K. Lee, Y.D. Yoon, C.W. Lee, K.H. Lee, G. Han, K.H. Yang, Y.J. Kim, Y. Kim, and S.B. Han. 2007. Inhibition of human ovarian tumor growth by cytokine-induced killer cells. Archives of Pharmacal Research 30: 1464–1470.

    Article  CAS  PubMed  Google Scholar 

  • Kradin, R.L., J.T. Kurnick, D.S. Lazarus, F.I. Preffer, S.M. Dubinett, C.E. Pinto, J. Gifford, E. Davidson, B. Grove, R.J. Callahan, et al. 1989. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. The Lancet 1: 577–580.

    Article  CAS  Google Scholar 

  • Liu, L., W. Zhang, X. Qi, H. Li, J. Yu, S. Wei, X. Hao, and X. Ren. 2012. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clinical Cancer Research 18: 1751–1759.

    Article  CAS  PubMed  Google Scholar 

  • Liu, P., L. Chen, and X. Huang. 2009. The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo. Cancer Biotherapy Radiopharmaceuticals 24: 91–98.

    Article  CAS  PubMed  Google Scholar 

  • Lotze, M.T., E.A. Grimm, A. Mazumder, J.L. Strausser, and S.A. Rosenberg. 1981. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Research 41: 4420–4425.

    CAS  PubMed  Google Scholar 

  • Mcdermott, D.F., M.M. Regan, J.I. Clark, L.E. Flaherty, G.R. Weiss, T.F. Logan, J.M. Kirkwood, M.S. Gordon, J.A. Sosman, M.S. Ernstoff, C.P. Tretter, W.J. Urba, J.W. Smith, K.A. Margolin, J.W. Mier, J.A. Gollob, J.P. Dutcher, and M.B. Atkins. 2005. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 23: 133–141.

    Article  CAS  PubMed  Google Scholar 

  • Motzer, R.J., N. Agarwal, C. Beard, S. Bhayani, G.B. Bolger, M.A. Carducci, S.S. Chang, T.K. Choueiri, S.L. Hancock, G.R. Hudes, E. Jonasch, D. Josephson, T.M. Kuzel, E.G. Levine, D.W. Lin, K.A. Margolin, M.D. Michaelson, T. Olencki, R. Pili, T.W. Ratliff, B.G. Redman, C.N. Robertson, C.J. Ryan, J. Sheinfeld, P.E. Spiess, J. Wang, R.B. Wilder, and National Comprehensive Cancer N. 2011. Kidney cancer. Journal of the National Comprehensive Cancer Network 9: 960–977.

    CAS  PubMed  Google Scholar 

  • Motzer, R.J., T.E. Hutson, P. Tomczak, M.D. Michaelson, R.M. Bukowski, S. Oudard, S. Negrier, C. Szczylik, R. Pili, G.A. Bjarnason, X. Garcia-Del-Muro, J.A. Sosman, E. Solska, G. Wilding, J.A. Thompson, S.T. Kim, I. Chen, X. Huang, and R.A. Figlin. 2009. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 27: 3584–3590.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Mule, J.J., S. Shu, S.L. Schwarz, and S.A. Rosenberg. 1984. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225: 1487–1489.

    Article  CAS  PubMed  Google Scholar 

  • Nagashima, Y., N. Kuroda, and M. Yao. 2013. Transition of organizational category on renal cancer. Japanese Journal of Clinical Oncology 43: 233–242.

    Article  PubMed  Google Scholar 

  • Ochoa, A.C., G. Gromo, B.J. Alter, P.M. Sondel, and F.H. Bach. 1987. Long-term growth of lymphokine-activated killer (LAK) cells: Role of anti-CD3, beta-IL 1, interferon-gamma and -beta. The Journal of Immunology 138: 2728–2733.

    CAS  PubMed  Google Scholar 

  • Parkhurst, M.R., J.P. Riley, M.E. Dudley, and S.A. Rosenberg. 2011. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clinical Cancer Research 17: 6287–6297.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Pievani, A., G. Borleri, D. Pende, L. Moretta, A. Rambaldi, J. Golay, and M. Introna. 2011. Dual-functional capability of CD3 + CD56 + CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 118: 3301–3310.

    Article  CAS  PubMed  Google Scholar 

  • Rasmussen, N., and W.K. Rathmell. 2011. Looking beyond inhibition of VEGF/mTOR: Emerging targets for renal cell carcinoma drug development. Current Clinical Pharmacology 6: 199–206.

    Article  CAS  PubMed  Google Scholar 

  • Restifo, N.P., M.E. Dudley, and S.A. Rosenberg. 2012. Adoptive immunotherapy for cancer: Harnessing the T cell response. Nature Reviews Immunology 12: 269–281.

    Article  CAS  PubMed  Google Scholar 

  • Rini, B.I., and M.B. Atkins. 2009. Resistance to targeted therapy in renal-cell carcinoma. The Lancet Oncology 10: 992–1000.

    Article  CAS  PubMed  Google Scholar 

  • Rosenberg, S.A., M.T. Lotze, L.M. Muul, S. Leitman, A.E. Chang, S.E. Ettinghausen, Y.L. Matory, J.M. Skibber, E. Shiloni, J.T. Vetto, et al. 1985a. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New England Journal of Medicine 313: 1485–1492.

    Article  CAS  PubMed  Google Scholar 

  • Rosenberg, S.A., M.T. Lotze, J.C. Yang, S.L. Topalian, A.E. Chang, D.J. Schwartzentruber, P. Aebersold, S. Leitman, W.M. Linehan, C.A. Seipp, et al. 1993. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. Journal of the National Cancer Institute 85: 622–632.

    Article  CAS  PubMed  Google Scholar 

  • Rosenberg, S.A., J.J. Mule, P.J. Spiess, C.M. Reichert, and S.L. Schwarz. 1985b. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. Journal of Experimental Medicine 161: 1169–1188.

    Article  CAS  PubMed  Google Scholar 

  • Scelo, G., and P. Brennan. 2007. The epidemiology of bladder and kidney cancer. Nature Clinical Practice Urology 4: 205–217.

    Article  PubMed  Google Scholar 

  • Schmidt-Wolf, G.D., R.S. Negrin, and I.G. Schmidt-Wolf. 1997. Activated T cells and cytokine-induced CD3 + CD56 + killer cells. Annals of Hematology 74: 51–56.

    Article  CAS  PubMed  Google Scholar 

  • Schmidt-Wolf, I.G., S. Finke, B. Trojaneck, A. Denkena, P. Lefterova, N. Schwella, H.G. Heuft, G. Prange, M. Korte, M. Takeya, T. Dorbic, A. Neubauer, B. Wittig, and D. Huhn. 1999. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. British Journal of Cancer 81: 1009–1016.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Schmidt-Wolf, I.G., P. Lefterova, V. Johnston, C. Scheffold, M. Csipai, B.A. Mehta, T. Tsuruo, D. Huhn, and R.S. Negrin. 1996. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cellular Immunology 169: 85–90.

    Article  CAS  PubMed  Google Scholar 

  • Schmidt-Wolf, I.G., R.S. Negrin, H.P. Kiem, K.G. Blume, and I.L. Weissman. 1991. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. Journal of Experimental Medicine 174: 139–149.

    Article  CAS  PubMed  Google Scholar 

  • Sternberg, C.N., I.D. Davis, J. Mardiak, C. Szczylik, E. Lee, J. Wagstaff, C.H. Barrios, P. Salman, O.A. Gladkov, A. Kavina, J.J. Zarba, M. Chen, L. Mccann, L. Pandite, D.F. Roychowdhury, and R.E. Hawkins. 2010. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. Journal of Clinical Oncology 28: 1061–1068.

    Article  CAS  PubMed  Google Scholar 

  • Tamaskar, I., J. Dhillon, and R. Pili. 2011. Resistance to angiogenesis inhibitors in renal cell carcinoma. Clinical Advances in Hematology and Oncology 9: 101–110.

    PubMed  Google Scholar 

  • Thanendrarajan, S., Y. Kim, and I. Schmidt-Wolf. 2012. New adoptive immunotherapy strategies for solid tumours with CIK cells. Expert Opinion on Biological Therapy 12: 565–572.

    Article  CAS  PubMed  Google Scholar 

  • Thiounn, N., C. Mathiot, T. Flam, E. Tartour, C. Peyret, I. Joyeux, J.P. Abecassis, M. Zerbib, W.H. Fridman, and B. Debre. 1994. CD4 TIL (Tumor Infiltrating Lymphocytes) induce complete response in patients treated with IL-2 (Interleukin-2). Preliminary study. Journal of Urology (Paris) 100: 185–188.

    CAS  Google Scholar 

  • Thompson, J.A., D.J. Lee, C.G. Lindgren, L.A. Benz, C. Collins, W.P. Shuman, D. Levitt, and A. Fefer. 1989. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells. Cancer Research 49: 235–240.

    CAS  PubMed  Google Scholar 

  • Tomita, Y., A. Katagiri, K. Saito, T. Imai, T. Saito, T. Tanikawa, M. Terunuma, T. Nishiyama, and K. Takahashi. 1998. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: Long-term results. International Journal of Urology 5: 16–21.

    Article  CAS  PubMed  Google Scholar 

  • Topalian, S.L., D. Solomon, F.P. Avis, A.E. Chang, D.L. Freerksen, W.M. Linehan, M.T. Lotze, C.N. Robertson, C.A. Seipp, P. Simon, et al. 1988. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: A pilot study. Journal of Clinical Oncology 6: 839–853.

    CAS  PubMed  Google Scholar 

  • Verneris, M.R., J. Baker, M. Edinger, and R.S. Negrin. 2002. Studies of ex vivo activated and expanded CD8 + NK-T cells in humans and mice. Journal of Clinical Immunology 22: 131–136.

    Article  CAS  PubMed  Google Scholar 

  • Verneris, M.R., M. Karami, J. Baker, A. Jayaswal, and R.S. Negrin. 2004. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8 + T cells. Blood 103: 3065–3072.

    Article  CAS  PubMed  Google Scholar 

  • Wang, H., F.J. Zhou, Q.J. Wang, Z.K. Qin, L.X. Huang, Z.W. Liu, H. Han, Y.Q. Li, S.P. Chen, and J.C. Xia. 2006. Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma—A report of ten cases. Ai Zheng 25: 625–630.

    CAS  PubMed  Google Scholar 

  • Wang, Z., Y. Zhang, Y. Liu, L. Wang, L. Zhao, T. Yang, C. He, Y. Song, and Q. Gao. 2014. Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients. Journal of Immunotherapy 37: 43–50.

    Article  CAS  PubMed  Google Scholar 

  • Wersall, P., and H. Mellstedt. 1995. Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and alpha-IFN. Medical Oncology 12: 69–77.

    Article  CAS  PubMed  Google Scholar 

  • Wu, R., M.A. Forget, J. Chacon, C. Bernatchez, C. Haymaker, J.Q. Chen, P. Hwu, and L.G. Radvanyi. 2012. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: Current status and future outlook. Cancer Journal 18: 160–175.

    Article  CAS  Google Scholar 

  • Yang, J.C., R.M. Sherry, S.M. Steinberg, S.L. Topalian, D.J. Schwartzentruber, P. Hwu, C.A. Seipp, L. Rogers-Freezer, K.E. Morton, D.E. White, D.J. Liewehr, M.J. Merino, and S.A. Rosenberg. 2003. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. Journal of Clinical Oncology 21: 3127–3132.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Yu, J., W. Zhang, H. Jiang, H. Li, S. Cao, and X. Ren. 2008. CD4 + T cells in CIKs (CD4 + CIKs) reversed resistance to fas-mediated apoptosis through CD40/CD40L ligation rather than IFN-gamma stimulation. Cancer Biotherapy and Radiopharmaceuticals 23: 342–354.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Zhan, H.L., X. Gao, X.Y. Pu, W. Li, Z.J. Li, X.F. Zhou, and J.G. Qiu. 2012. A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma. Chinese Medical Journal (England) 125: 3771–3777.

    Google Scholar 

  • Zhang, S., S.J. Jiang, C.Q. Zhang, H.M. Wang, and C.X. Bai. 2005a. Antitumour activities of cytokine-induced killer cells and dendritic cells in vitro and in vivo. Chinese Medical Journal (England) 118: 1308–1312.

    CAS  Google Scholar 

  • Zhang, Y., J. Wang, Y. Wang, X.C. Lu, H. Fan, Y. Liu, Y. Zhang, K.C. Feng, W.Y. Zhang, M.X. Chen, X. Fu, and W.D. Han. 2013. Autologous CIK cell immunotherapy in patients with renal cell carcinoma after radical nephrectomy. Clinical and Development Immunology 2013: 195691.

    Article  Google Scholar 

  • Zhang, Y.S., F.J. Yuan, G.F. Jia, J.F. Zhang, L.Y. Hu, L. Huang, J. Wang, and Z.Q. Dai. 2005b. CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R. World Journal of Gastroenterology 11: 3339–3345.

    PubMed  Google Scholar 

  • Zhao, Q., H. Zhang, Y. Li, J. Liu, X. Hu, and L. Fan. 2010. Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro. Journal of Experiment and Clinical Cancer Research 29: 118.

    Article  Google Scholar 

  • Zhu, H.H., K.L. Xu, X.Y. Pan, J.Q. Liu, F.X. Chen, and Y.H. Huang. 2003. Specific anti-leukemic cell effect mediated by dendritic cells pulsed with chronic myelogenous leukemia lysate antigen in vitro. Zhongguo Shi Yan Xue Ye Xue Za Zhi 11: 278–281.

    PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the research grant of the Chungbuk National University in 2012.

Conflict of interest

The authors declare no conflicts of interest.

Author information

Authors and Affiliations

  1. College of Pharmacy, Chungbuk National University, 52 Naesoodong, Heungduk, Cheongju, Chungbuk, 361-763, South Korea

    Ji Sung Kim, In Sung Chung, Sang Hee Lim, Yunsoo Park, Mi Jeong Park, Ju Young Kim, Yong Guk Kim, Jin Tae Hong, Youngsoo Kim & Sang-Bae Han

Authors
  1. Ji Sung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. In Sung Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sang Hee Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yunsoo Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mi Jeong Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ju Young Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yong Guk Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jin Tae Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Youngsoo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sang-Bae Han
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sang-Bae Han.

Additional information

Ji Sung Kim and In Sung Chung have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, J.S., Chung, I.S., Lim, S.H. et al. Preclinical and clinical studies on cytokine-induced killer cells for the treatment of renal cell carcinoma. Arch. Pharm. Res. 37, 559–566 (2014). https://doi.org/10.1007/s12272-014-0381-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-014-0381-x

Keywords

Search

Navigation